Compare OXLC & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OXLC | SPTX |
|---|---|---|
| Founded | 2010 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 982.8M | 1.1B |
| IPO Year | N/A | 2026 |
| Metric | OXLC | SPTX |
|---|---|---|
| Price | $8.51 | $21.27 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 802.2K | 124.7K |
| Earning Date | 11-01-2023 | N/A |
| Dividend Yield | ★ 18.86% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.20 | N/A |
| Revenue | ★ $130,145,365.00 | N/A |
| Revenue This Year | $136.15 | N/A |
| Revenue Next Year | $5.51 | N/A |
| P/E Ratio | $7.21 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.18 | $17.59 |
| 52 Week High | $18.20 | $22.98 |
| Indicator | OXLC | SPTX |
|---|---|---|
| Relative Strength Index (RSI) | 35.20 | 58.35 |
| Support Level | $8.11 | $18.47 |
| Resistance Level | $9.24 | $22.12 |
| Average True Range (ATR) | 0.19 | 1.76 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 0.63 | 74.03 |
Oxford Lane Capital Corp is a non-diversified closed-end management investment company. The fund's investment objective is to maximize its portfolio's risk-adjusted total return over its investment horizon. Its current focus is to seek that return by investing in equity and junior tranches of CLO(collateralized loan obligation) vehicles, which are collateralized by a diverse portfolio of senior loans, and which generally have little to no exposure to real estate loans, mortgage loans or pools of consumer-based debt, such as credit card receivables or auto loans. Its investment plan also includes investing in warehouse facilities, which are financing structures intended to aggregate senior loans that may be used to form the basis of a CLO vehicle.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.